{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:29:48Z","timestamp":1746786588341},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00347-022-01650-2","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:13:58Z","timestamp":1653326038000},"page":"664-674","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lymphome des Auges und seiner Adnexe"],"prefix":"10.1007","volume":"119","author":[{"given":"Falko","family":"Fend","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Bonzheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinodh","family":"Kakkassery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig M.","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"1650_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.14025","volume":"173","author":"F Fend","year":"2016","unstructured":"Fend\u00a0F, Ferreri\u00a0AJ, Coupland\u00a0SE (2016) How we diagnose and treat vitreoretinal lymphoma. Br J Haematol 173:680\u2013692. https:\/\/doi.org\/10.1111\/bjh.14025","journal-title":"Br J Haematol"},{"key":"1650_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.beha.2016.1011.1002","volume":"30","author":"M Sassone","year":"2017","unstructured":"Sassone\u00a0M, Ponzoni\u00a0M, Ferreri\u00a0AJ (2017) Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. Best Pract Res Clin Haematol 30:118\u2013130. https:\/\/doi.org\/10.1016\/j.beha.2016.1011.1002","journal-title":"Best Pract Res Clin Haematol"},{"key":"1650_CR3","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.3390\/cancers13163921","volume":"13","author":"B Sobolewska","year":"2021","unstructured":"Sobolewska\u00a0B, Chee\u00a0SP, Zaguia\u00a0F, Goldstein\u00a0DA, Smith\u00a0JR, Fend\u00a0F, Mochizuki\u00a0M, Zierhut\u00a0M (2021) Vitreoretinal Lymphoma. Cancers 13:3921. https:\/\/doi.org\/10.3390\/cancers13163921","journal-title":"Cancers"},{"key":"1650_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1182\/blood.2020008235","volume":"138","author":"C Soussain","year":"2021","unstructured":"Soussain\u00a0C, Malaise\u00a0D, Cassoux\u00a0N (2021) Primary vitreoretinal lymphoma: a\u00a0diagnostic and management challenge. Blood 138:1519\u20131534. https:\/\/doi.org\/10.1182\/blood.2020008235","journal-title":"Blood"},{"key":"1650_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","volume":"4","author":"JS Pulido","year":"2018","unstructured":"Pulido\u00a0JS, Johnston\u00a0PB, Nowakowski\u00a0GS, Castellino\u00a0A, Raja\u00a0H (2018) The diagnosis and treatment of primary vitreoretinal lymphoma: a\u00a0review. Int J Retina Vitreous 4:18. https:\/\/doi.org\/10.1186\/s40942-018-0120-4","journal-title":"Int J Retina Vitreous"},{"key":"1650_CR6","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"S Swerdlow","year":"2017","unstructured":"Swerdlow\u00a0S, Campo\u00a0E, Harris\u00a0N, Jaffe\u00a0E, Pileri\u00a0S, Stein\u00a0H, Thiele\u00a0J, Arber\u00a0DA, Hasserjian\u00a0RP, Le Beau\u00a0MM et\u00a0al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4.\u00a0Aufl. Bd. 2. International Agency for Research on Cancer, Lyon","edition":"4"},{"key":"1650_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","volume":"18","author":"SA Grimm","year":"2007","unstructured":"Grimm\u00a0SA, Pulido\u00a0JS, Jahnke\u00a0K, Schiff\u00a0D, Hall\u00a0AJ, Shenkier\u00a0TN, Siegal\u00a0T, Doolittle\u00a0ND, Batchelor\u00a0T, Herrlinger\u00a0U et\u00a0al (2007) Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol 18:1851\u20131855. https:\/\/doi.org\/10.1093\/annonc\/mdm340","journal-title":"Ann Oncol"},{"key":"1650_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/09273940903168696","volume":"17","author":"SE Coupland","year":"2009","unstructured":"Coupland\u00a0SE, Chan\u00a0CC, Smith\u00a0J (2009) Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm 17:227\u2013237. https:\/\/doi.org\/10.1080\/09273940903168696","journal-title":"Ocul Immunol Inflamm"},{"key":"1650_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jnen\/nlz125","volume":"79","author":"C Bodor","year":"2020","unstructured":"Bodor\u00a0C, Alpar\u00a0D, Marosvari\u00a0D, Galik\u00a0B, Rajnai\u00a0H, Batai\u00a0B, Nagy\u00a0A, Kajtar\u00a0B, Burjan\u00a0A, Deak\u00a0B et\u00a0al (2020) Molecular subtypes and genomic profile of primary central nervous system lymphoma. J\u00a0Neuropathol Exp Neurol 79:176\u2013183. https:\/\/doi.org\/10.1093\/jnen\/nlz125","journal-title":"J Neuropathol Exp Neurol"},{"key":"1650_CR10","doi-asserted-by":"publisher","first-page":"2021004212","DOI":"10.1182\/bloodadvances.2021004212","volume":"27","author":"I Bonzheim","year":"2021","unstructured":"Bonzheim\u00a0I, Sander\u00a0P, Salmeron-Villalobos\u00a0J, S\u00fcsskind\u00a0D, Szurman\u00a0P, Gekeler\u00a0F, Spitzer\u00a0MS, Steinhilber\u00a0J, Kohler\u00a0E, B\u00fcssgen\u00a0M et al (2021) The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv 27:2021004212","journal-title":"Blood Adv"},{"key":"1650_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy\u00a0B, Roemer\u00a0MG, Stewart\u00a0C, Tan\u00a0Y, Abo\u00a0RP, Zhang\u00a0L, Dunford\u00a0AJ, Meredith\u00a0DM, Thorner\u00a0AR, Jordanova\u00a0ES et\u00a0al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869\u2013881. https:\/\/doi.org\/10.1182\/blood-2015-10-673236","journal-title":"Blood"},{"key":"1650_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/WCO.0000000000000759","volume":"32","author":"KG Ho","year":"2019","unstructured":"Ho\u00a0KG, Grommes\u00a0C (2019) Molecular profiling of primary central nervous system lymphomas\u2014predictive and prognostic value? Curr Opin Neurol 32:886\u2013894. https:\/\/doi.org\/10.1097\/WCO.0000000000000759","journal-title":"Curr Opin Neurol"},{"key":"1650_CR13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.233783","author":"J Lee","year":"2020","unstructured":"Lee\u00a0J, Kim\u00a0B, Lee\u00a0H, Park\u00a0H, Byeon\u00a0SH, Choi\u00a0JR, Lee\u00a0SC, Lee\u00a0ST, Lee\u00a0CS (2020) Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.233783","journal-title":"Haematologica"},{"key":"1650_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/sj.leu.2405019","volume":"22","author":"M Montesinos-Rongen","year":"2008","unstructured":"Montesinos-Rongen\u00a0M, Brunn\u00a0A, Bentink\u00a0S, Basso\u00a0K, Lim\u00a0WK, Klapper\u00a0W, Schaller\u00a0C, Reifenberger\u00a0G, Rubenstein\u00a0J, Wiestler\u00a0OD et al (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a\u00a0late germinal center B cell. Leukemia 22:400\u2013405. https:\/\/doi.org\/10.1038\/sj.leu.2405019","journal-title":"Leukemia"},{"key":"1650_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","volume":"3","author":"N Nayyar","year":"2019","unstructured":"Nayyar\u00a0N, White\u00a0MD, Gill\u00a0CM, Lastrapes\u00a0M, Bertalan\u00a0M, Kaplan\u00a0A, D\u2019Andrea\u00a0MR, Bihun\u00a0I, Kaneb\u00a0A, Dietrich\u00a0J et al (2019) MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B\u2011cell lymphomas. Blood Adv 3:375\u2013383. https:\/\/doi.org\/10.1182\/bloodadvances.2018027672","journal-title":"Blood Adv"},{"key":"1650_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy\u00a0B, Stewart\u00a0C, Dunford\u00a0AJ, Kim\u00a0J, Kamburov\u00a0A, Redd\u00a0RA, Lawrence\u00a0MS, Roemer\u00a0MGM, Li\u00a0AJ, Ziepert\u00a0M et\u00a0al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"key":"1650_CR17","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz\u00a0R, Wright\u00a0GW, Huang\u00a0DW, Johnson\u00a0CA, Phelan\u00a0JD, Wang\u00a0JQ, Roulland\u00a0S, Kasbekar\u00a0M, Young\u00a0RM, Shaffer\u00a0AL et al (2018) Genetics and pathogenesis of diffuse large B\u2011cell lymphoma. N\u00a0Engl J Med 378:1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"key":"1650_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","volume":"126","author":"I Bonzheim","year":"2015","unstructured":"Bonzheim\u00a0I, Giese\u00a0S, Deuter\u00a0C, Susskind\u00a0D, Zierhut\u00a0M, Waizel\u00a0M, Szurman\u00a0P, Federmann\u00a0B, Schmidt\u00a0J, Quintanilla-Martinez\u00a0L et al (2015) High frequency of MYD88 mutations in vitreoretinal B\u2011cell lymphoma: a\u00a0valuable tool to improve diagnostic yield of vitreous aspirates. Blood 126:76\u201379. https:\/\/doi.org\/10.1182\/blood-2015-01-620518","journal-title":"Blood"},{"key":"1650_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jamaophthalmol.2013.334","volume":"131","author":"DR Salomao","year":"2013","unstructured":"Salomao\u00a0DR, Pulido\u00a0JS, Johnston\u00a0PB, Canal-Fontcuberta\u00a0I, Feldman\u00a0AL (2013) Vitreoretinal presentation of secondary large B\u2011cell lymphoma in patients with systemic lymphoma. JAMA Ophthalmol 131:1151\u20131158. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.334","journal-title":"JAMA Ophthalmol"},{"key":"1650_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/cas.12388","volume":"105","author":"L Wang","year":"2014","unstructured":"Wang\u00a0L, Sato-Otsubo\u00a0A, Sugita\u00a0S, Takase\u00a0H, Mochizuki\u00a0M, Usui\u00a0Y, Goto\u00a0H, Koyama\u00a0T, Akiyama\u00a0H, Miura\u00a0O et al (2014) High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays. Cancer Sci 105:592\u2013599. https:\/\/doi.org\/10.1111\/cas.12388","journal-title":"Cancer Sci"},{"key":"1650_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ejh.13191","volume":"102","author":"I Yonese","year":"2019","unstructured":"Yonese\u00a0I, Takase\u00a0H, Yoshimori\u00a0M, Onozawa\u00a0E, Tsuzura\u00a0A, Miki\u00a0T, Mochizuki\u00a0M, Miura\u00a0O, Arai\u00a0A (2019) CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential. Eur J Haematol 102:191\u2013196. https:\/\/doi.org\/10.1111\/ejh.13191","journal-title":"Eur J Haematol"},{"key":"1650_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1442-9071.2008.01843.x","volume":"36","author":"SE Coupland","year":"2008","unstructured":"Coupland\u00a0SE, Damato\u00a0B (2008) Understanding intraocular lymphomas. Clin Experiment Ophthalmol 36:564\u2013578. https:\/\/doi.org\/10.1111\/j.1442-9071.2008.01843.x","journal-title":"Clin Experiment Ophthalmol"},{"key":"1650_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1634\/theoncologist.2012-0425","volume":"18","author":"M Ponzoni","year":"2013","unstructured":"Ponzoni\u00a0M, Govi\u00a0S, Licata\u00a0G, Mappa\u00a0S, Resti\u00a0GA, Politi\u00a0LS, Spagnuolo\u00a0L, Di Cairano\u00a0E, Doglioni\u00a0C, Ferreri\u00a0AJ (2013) A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma. Oncologist 18:876\u2013884. https:\/\/doi.org\/10.1634\/theoncologist.2012-0425","journal-title":"Oncologist"},{"key":"1650_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/path.1984","volume":"209","author":"E Chanudet","year":"2006","unstructured":"Chanudet\u00a0E, Zhou\u00a0Y, Bacon\u00a0CM, Wotherspoon\u00a0AC, Muller-Hermelink\u00a0HK, Adam\u00a0P, Dong\u00a0HY, de Jong\u00a0D, Li\u00a0Y, Wei\u00a0R et al (2006) Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J\u00a0Pathol 209:344\u2013351. https:\/\/doi.org\/10.1002\/path.1984","journal-title":"J Pathol"},{"key":"1650_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/jnci\/djh102","volume":"96","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri\u00a0AJ, Guidoboni\u00a0M, Ponzoni\u00a0M, De Conciliis\u00a0C, Dell\u2019Oro\u00a0S, Fleischhauer\u00a0K, Caggiari\u00a0L, Lettini\u00a0AA, Dal Cin\u00a0E, Ieri\u00a0R et\u00a0al (2004) Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J\u00a0Natl Cancer Inst 96:586\u2013594. https:\/\/doi.org\/10.1093\/jnci\/djh102","journal-title":"J Natl Cancer Inst"},{"key":"1650_CR26","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1158\/1078-0432.CCR-08-0676","volume":"14","author":"M Ponzoni","year":"2008","unstructured":"Ponzoni\u00a0M, Ferreri\u00a0AJ, Guidoboni\u00a0M, Lettini\u00a0AA, Cangi\u00a0MG, Pasini\u00a0E, Sacchi\u00a0L, Pecciarini\u00a0L, Grassi\u00a0S, Dal Cin\u00a0E et\u00a0al (2008) Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods. Clin Cancer Res 14:5794\u20135800. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0676","journal-title":"Clin Cancer Res"},{"key":"1650_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/01.pas.0000249445.28713.88","volume":"31","author":"A Ruiz","year":"2007","unstructured":"Ruiz\u00a0A, Reischl\u00a0U, Swerdlow\u00a0SH, Hartke\u00a0M, Streubel\u00a0B, Procop\u00a0G, Tubbs\u00a0RR, Cook\u00a0JR (2007) Extranodal marginal zone B\u2011cell lymphomas of the ocular adnexa: multiparameter analysis of 34\u00a0cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am J Surg Pathol 31:792\u2013802. https:\/\/doi.org\/10.1097\/01.pas.0000249445.28713.88","journal-title":"Am J Surg Pathol"},{"key":"1650_CR28","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3109\/10428194.2010.513751","volume":"51","author":"D Zhang","year":"2010","unstructured":"Zhang\u00a0D, Dong\u00a0L, Li\u00a0H, Jin\u00a0H, Ye\u00a0H, Zhou\u00a0X, Gao\u00a0Z, Dong\u00a0G, Zhu\u00a0J, Liu\u00a0H et al (2010) Ocular adnexal mucosa-associated lymphoid tissue lymphoma in Northern China: high frequency of numerical chromosomal changes and no evidence of an association with Chlamydia psittaci. Leuk Lymphoma 51:2031\u20132038. https:\/\/doi.org\/10.3109\/10428194.2010.513751","journal-title":"Leuk Lymphoma"},{"key":"1650_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/jnci\/djj373","volume":"98","author":"AJ Ferreri","year":"2006","unstructured":"Ferreri\u00a0AJ, Ponzoni\u00a0M, Guidoboni\u00a0M, Resti\u00a0AG, Politi\u00a0LS, Cortelazzo\u00a0S, Demeter\u00a0J, Zallio\u00a0F, Palmas\u00a0A, Muti\u00a0G et al (2006) Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a\u00a0multicenter prospective trial. J\u00a0Natl Cancer Inst 98:1375\u20131382. https:\/\/doi.org\/10.1093\/jnci\/djj373","journal-title":"J Natl Cancer Inst"},{"key":"1650_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/path.2466","volume":"217","author":"E Chanudet","year":"2009","unstructured":"Chanudet\u00a0E, Ye\u00a0H, Ferry\u00a0J, Bacon\u00a0CM, Adam\u00a0P, Muller-Hermelink\u00a0HK, Radford\u00a0J, Pileri\u00a0SA, Ichimura\u00a0K, Collins\u00a0VP et al (2009) A20 deletion is associated with copy number gain at the TNFA\/B\/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J\u00a0Pathol 217:420\u2013430. https:\/\/doi.org\/10.1002\/path.2466","journal-title":"J Pathol"},{"key":"1650_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2016.07.003","volume":"39","author":"MQ Du","year":"2016","unstructured":"Du\u00a0MQ (2016) MALT lymphoma: A paradigm of NF-kappaB dysregulation. Semin Cancer Biol 39:49\u201360. https:\/\/doi.org\/10.1016\/j.semcancer.2016.07.003","journal-title":"Semin Cancer Biol"},{"key":"1650_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040986","author":"P Johansson","year":"2020","unstructured":"Johansson\u00a0P, Klein-Hitpass\u00a0L, Budeus\u00a0B, Kuhn\u00a0M, Lauber\u00a0C, Seifert\u00a0M, Roeder\u00a0I, Pfortner\u00a0R, Stuschke\u00a0M, Duhrsen\u00a0U et al (2020) Identifying genetic lesions in ocular adnexal extranodal marginal zone lymphomas of the MALT subtype by whole genome, whole exome and targeted sequencing. Cancers. https:\/\/doi.org\/10.3390\/cancers12040986","journal-title":"Cancers"},{"key":"1650_CR33","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","volume":"127","author":"E Zucca","year":"2016","unstructured":"Zucca\u00a0E, Bertoni\u00a0F (2016) The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood 127:2082\u20132092. https:\/\/doi.org\/10.1182\/blood-2015-12-624304","journal-title":"Blood"},{"key":"1650_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5858\/arpa.2018-0092-OA","volume":"143","author":"A Behdad","year":"2019","unstructured":"Behdad\u00a0A, Zhou\u00a0XY, Gao\u00a0J, Raparia\u00a0K, Dittman\u00a0D, Green\u00a0SJ, Qi\u00a0C, Betz\u00a0B, Bryar\u00a0P, Chen\u00a0Q et\u00a0al (2019) High frequency of MYD88 L265P mutation in primary ocular adnexal marginal zone lymphoma and its clinicopathologic correlation: a study from a\u00a0single institution. Arch Pathol Lab Med 143:483\u2013493. https:\/\/doi.org\/10.5858\/arpa.2018-0092-OA","journal-title":"Arch Pathol Lab Med"},{"key":"1650_CR35","doi-asserted-by":"crossref","unstructured":"BIOMED-2 Konsortium (2012) Leukemia 26(10):2159\u20132171","DOI":"10.1038\/leu.2012.246"},{"key":"1650_CR36","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1167\/iovs.05-0401","volume":"46","author":"SE Coupland","year":"2005","unstructured":"Coupland\u00a0SE, Hummel\u00a0M, Muller\u00a0HH, Stein\u00a0H (2005) Molecular analysis of immunoglobulin genes in primary intraocular lymphoma. Invest Ophthalmol Vis Sci 46:3507\u20133514. https:\/\/doi.org\/10.1167\/iovs.05-0401","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1650_CR37","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.18632\/oncotarget.14008","volume":"8","author":"AK Cani","year":"2017","unstructured":"Cani\u00a0AK, Hovelson\u00a0DH, Demirci\u00a0H, Johnson\u00a0MW, Tomlins\u00a0SA, Rao\u00a0RC (2017) Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Oncotarget 8:7989\u20137998. https:\/\/doi.org\/10.18632\/oncotarget.14008","journal-title":"Oncotarget"},{"key":"1650_CR38","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamaophthalmol.2018.2887","volume":"136","author":"LS Hiemcke-Jiwa","year":"2018","unstructured":"Hiemcke-Jiwa\u00a0LS, Ten Dam-van Loon\u00a0NH, Leguit\u00a0RJ, Nierkens\u00a0S, Ossewaarde-van\u00a0NJ, de Boer\u00a0JH, Roholl\u00a0FF, de Weger\u00a0RA, Huibers\u00a0MMH, de Groot-Mijnes\u00a0JDF et al (2018) Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction. JAMA Ophthalmol 136:1098\u20131104. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.2887","journal-title":"JAMA Ophthalmol"},{"key":"1650_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/blood.2019000022","volume":"134","author":"WJ Tan","year":"2019","unstructured":"Tan\u00a0WJ, Wang\u00a0MM, Ricciardi-Castagnoli\u00a0P, Tang\u00a0T, Chee\u00a0SP, Lim\u00a0TS, Chan\u00a0ASY (2019) Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis. Blood 134:709\u2013712. https:\/\/doi.org\/10.1182\/blood.2019000022","journal-title":"Blood"},{"key":"1650_CR40","doi-asserted-by":"publisher","unstructured":"Chan C\u2011C, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT et al (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.  Oncologist 16:1589\u20131599. https:\/\/doi.org\/10.1634\/theoncologist.2011-0210","DOI":"10.1634\/theoncologist.2011-0210"},{"key":"1650_CR41","doi-asserted-by":"publisher","unstructured":"Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. \nGraefes Arch Clin Exp Ophthalmol 242:901\u2013913. https:\/\/doi.org\/10.1007\/s00417-004-0973-0","DOI":"10.1007\/s00417-004-0973-0"},{"key":"1650_CR42","doi-asserted-by":"publisher","unstructured":"Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma.\nClin Cancer Res 9:711\u2013715.  https:\/\/doi.org\/10.1016\/j.ajo.2003.10.009","DOI":"10.1016\/j.ajo.2003.10.009"},{"key":"1650_CR43","doi-asserted-by":"crossref","unstructured":"Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T (1986) Treatment of intraocular lymphoma with high-dose Ara\u2011C.Cancer 1;57:1273\u20131275. https:\/\/doi.org\/10.1002\/1097-0142(19860401)57:7<1273::aid-cncr2820570702>3.0.co;2-c","DOI":"10.1002\/1097-0142(19860401)57:7<1273::AID-CNCR2820570702>3.0.CO;2-C"},{"key":"1650_CR44","doi-asserted-by":"publisher","unstructured":"de Smet MD, Stark-Vancs V, Kohler DR, Smith J, Wittes R, Nussenblatt RB (1996) Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 121:442\u2013444. https:\/\/doi.org\/10.1016\/s0002-9394(14)70444-1","DOI":"10.1016\/s0002-9394(14)70444-1"},{"key":"1650_CR45","doi-asserted-by":"publisher","unstructured":"Hashida N, Nakai K, Saitoh N, Nishida K (2014) Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.  Graefes Arch Clin Exp Ophthalmol\n\n252:687\u2013693. https:\/\/doi.org\/10.1007\/s00417-014-2584-8","DOI":"10.1007\/s00417-014-2584-8"},{"key":"1650_CR46","doi-asserted-by":"publisher","unstructured":"Kaburaki T, Taoka K, Matsuda J, Yamashita H, Matsuda I, Tsuji H, Tanaka R, Nakazaki K, Nakamura F, Kamiya K et al (2017) Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B\u2011cell primary intraocular lymphoma. Brit J Haematol 179:246\u2013255. https:\/\/doi.org\/10.1111\/bjh.14848","DOI":"10.1111\/bjh.14848"},{"key":"1650_CR47","doi-asserted-by":"publisher","unstructured":"Soussain BC, Suzan F, Hoang-xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS Lymphoma or Intraocular Lymphoma. J Clin Oncol 1;19:742\u2013749. https:\/\/doi.org\/10.1200\/jco.2001.19.3.742","DOI":"10.1200\/jco.2001.19.3.742"},{"key":"1650_CR48","doi-asserted-by":"publisher","unstructured":"Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesqui\u00e8res H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A et al (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 97:1751\u20131756. https:\/\/doi.org\/10.3324\/haematol.2011.060434","DOI":"10.3324\/haematol.2011.060434"},{"key":"1650_CR49","doi-asserted-by":"publisher","unstructured":"Soussain C, Merle-B\u00e9ral H, Reux I, Sutton L, Fardeau C, Gerber S, Othman BT, Binet JL, Lehoang P, Leblond V (1996) A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 23:339\u2013345.  https:\/\/doi.org\/10.3109\/10428199609054837","DOI":"10.3109\/10428199609054837"},{"key":"1650_CR50","doi-asserted-by":"publisher","unstructured":"Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295\u20132305. https:\/\/doi.org\/10.1200\/jco.2006.09.9861","DOI":"10.1200\/jco.2006.09.9861"},{"key":"1650_CR51","doi-asserted-by":"publisher","unstructured":"Castellino A, Pulido JS, Johnston PB, Ristow KM, Bennani NN, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR et al (2019) Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience. Am J Haematol 94:291\u2013298.  https:\/\/doi.org\/10.1002\/ajh.25350","DOI":"10.1002\/ajh.25350"},{"key":"1650_CR52","doi-asserted-by":"publisher","unstructured":"Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, Houillier C, Hoang-Xuan K, Gyan E, Le Lez M\u2011L et al (2020) Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood 135:1811\u20131815.  https:\/\/doi.org\/10.1182\/blood.2019003073","DOI":"10.1182\/blood.2019003073"},{"key":"1650_CR53","doi-asserted-by":"publisher","unstructured":"Kagoya Y, Nannya Y, Nakamura F, Kurokawa M (2014) Gene expression profiles of central nervous system lymphoma predict poor survival in patients with diffuse large B\u2011cell lymphoma. Brit J Haematol 166:794\u2013797.  https:\/\/doi.org\/10.1111\/bjh.12902","DOI":"10.1111\/bjh.12902"},{"key":"1650_CR54","doi-asserted-by":"publisher","unstructured":"Belhouachi N, Xochelli A, Boudjoghra M, Lesty C, Cassoux N, Fardeau C, Tran THC, Choquet S, Sarker B, Houillier C et al (2020) Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Adv 4:1357\u20131366. https:\/\/doi.org\/10.1182\/bloodadvances.2019000980","DOI":"10.1182\/bloodadvances.2019000980"},{"key":"1650_CR55","doi-asserted-by":"publisher","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C\u2011J, Williams PM, Shaffer AL, Gerecitano J et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922\u2013926.\n https:\/\/doi.org\/10.1038\/nm.3884","DOI":"10.1038\/nm.3884"},{"key":"1650_CR56","doi-asserted-by":"publisher","unstructured":"Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B\u2011cell non-hodgkin lymphoma. J Clin Oncol 33:2803\u20132811.\nhttps:\/\/doi.org\/10.1200\/jco.2014.59.5363","DOI":"10.1200\/jco.2014.59.5363"},{"key":"1650_CR57","doi-asserted-by":"publisher","unstructured":"Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.\nCancer Immunol Immunother 60:61\u201373.  https:\/\/doi.org\/10.1007\/s00262-010-0919-9","DOI":"10.1007\/s00262-010-0919-9"},{"key":"1650_CR58","doi-asserted-by":"publisher","unstructured":"Zhu D, Corral LG, Fleming YW, Stein B (2008) Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. \nCancer Immunol Immunother 57:1849\u20131859. https:\/\/doi.org\/10.1007\/s00262-008-0512-7","DOI":"10.1007\/s00262-008-0512-7"},{"key":"1650_CR59","doi-asserted-by":"publisher","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345\u20131350.\n https:\/\/doi.org\/10.1126\/science.1177319","DOI":"10.1126\/science.1177319"},{"key":"1650_CR60","doi-asserted-by":"publisher","unstructured":"Zhu YX, Braggio E, Shi C\u2011X, Bruins LA, Schmidt JE, Van Wier S, Chang X\u2011B, Bjorklund CC, Fonseca R, Bergsagel PL et al (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771\u20134779. https:\/\/doi.org\/10.1182\/blood-2011-05-356063","DOI":"10.1182\/blood-2011-05-356063"},{"key":"1650_CR61","doi-asserted-by":"publisher","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. \nNat Rev Cancer 14:219\u2013232.\nhttps:\/\/doi.org\/10.1038\/nrc3702","DOI":"10.1038\/nrc3702"},{"key":"1650_CR62","doi-asserted-by":"publisher","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molu\u00e7on-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A et al (2019) Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201eproof of concept\u201c phase II study of the French oculo-cerebral Lymphoma (LOC) network and the Lymphoma study association (LYSA). \nAnn Oncol 30:621\u2013628.\nhttps:\/\/doi.org\/10.1093\/annonc\/mdz032","DOI":"10.1093\/annonc\/mdz032"},{"key":"1650_CR63","doi-asserted-by":"publisher","unstructured":"Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J et al (2018) Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.\nBlood Adv 2:1595\u20131607.\n https:\/\/doi.org\/10.1182\/bloodadvances.2017014845","DOI":"10.1182\/bloodadvances.2017014845"},{"key":"1650_CR64","doi-asserted-by":"publisher","unstructured":"Rubenstein JL, Treseler PA, Stewart PJ (2011) Regression of refractory intraocular large B\u2011cell lymphoma with lenalidomide monotherapy. J Clin Oncol 29:e595\u2013e597.\nhttps:\/\/doi.org\/10.1200\/jco.2011.34.7252","DOI":"10.1200\/jco.2011.34.7252"},{"key":"1650_CR65","doi-asserted-by":"publisher","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R et al (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u201aproof-of-concept\u2018 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. \nEur J Cancer 117:121\u2013130.\nhttps:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","DOI":"10.1016\/j.ejca.2019.05.024"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01650-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-022-01650-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01650-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T08:12:23Z","timestamp":1657095143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-022-01650-2"}},"subtitle":["Moderne pathologische Diagnostik und systemische Therapie"],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s00347-022-01650-2","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"14 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Fend, I.\u00a0Bonzheim, V.\u00a0Kakkassery, L.M.\u00a0Heindl und G.\u00a0Illerhaus geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}